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Human polynucleotide kinase/phosphatase (hPNKP) is an enzyme with dual phosphatase/kinase 
activities involved in the repair of damaged DNA.  Cancer cells depleted of hPNKP are more sensitive 
to ionizing agents (commonly used for cancer therapy), which makes hPNKP a potential target for 
cancer treatment.  Previously, our group has described the synthesis of polysubstituted imido-
piperidines using a multi component reaction (MCR).  Through screening a library of these drug-like 
compounds, we found that one of them, A12B4C3, binds with high affinity to hPNKP (IC50 = 7.4 µM).  
Furthermore, data showed A12B4C3 does not bind the enzyme in its active site, suggesting an 
allosteric mechanism. The identification of the inhibitor binding site has been previously attempted by 
using co-crystallization experiments, unsuccessfully.  Thus, we decided to use the photoaffinity 
labelling approach to gain a better understanding of the inhibition mechanism.  Hence, an increased 
knowledge of the inhibitor binding site would allow us able to design more efficient inhibitors by 
rational design. 
 
 
 
